Alps Advisors Inc. Buys New Stake in EQRx, Inc. (NASDAQ:EQRX)

Alps Advisors Inc. bought a new stake in EQRx, Inc. (NASDAQ:EQRXGet Rating) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 289,355 shares of the company’s stock, valued at approximately $1,357,000. Alps Advisors Inc. owned about 0.06% of EQRx at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Pictet Asset Management SA purchased a new position in EQRx in the second quarter valued at $49,000. ProShare Advisors LLC acquired a new position in EQRx in the second quarter valued at $72,000. Virtu Financial LLC acquired a new position in EQRx in the first quarter valued at $64,000. Prelude Capital Management LLC acquired a new position in EQRx in the first quarter valued at $79,000. Finally, Mirabella Financial Services LLP acquired a new position in EQRx in the first quarter valued at $81,000. Hedge funds and other institutional investors own 80.38% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have issued reports on EQRX. Jefferies Financial Group downgraded shares of EQRx from a “buy” rating to a “hold” rating and decreased their price objective for the company from $5.60 to $3.20 in a research note on Friday, November 11th. The Goldman Sachs Group downgraded shares of EQRx from a “buy” rating to a “neutral” rating and decreased their price objective for the company from $8.00 to $5.00 in a research note on Friday, November 11th. Finally, JPMorgan Chase & Co. downgraded shares of EQRx from a “neutral” rating to an “underweight” rating in a research note on Monday, November 14th. One analyst has rated the stock with a sell rating, two have issued a hold rating and two have issued a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $4.57.

EQRx Trading Down 0.6 %

Shares of EQRX opened at $3.32 on Friday. EQRx, Inc. has a fifty-two week low of $2.63 and a fifty-two week high of $9.99. The firm has a 50-day simple moving average of $4.81 and a 200-day simple moving average of $4.82.

EQRx Company Profile

(Get Rating)

EQRx, Inc, a pharmaceutical company, engages in developing medicines primarily for the treatment of oncology and immune-inflammatory diseases in the United States. The company's pre-registrational programs in Phase III clinical trial include Aumolertinib, an epidermal growth factor receptor (EGFR) inhibitor for the treatment of patients with EGFR-mutated non-small cell lung cancer (NSCLC); and Sugemalimab, an anti-programmed death-ligand 1 antibody for the treatment of Stage III and Stage IV NSCLC.

Featured Stories

Want to see what other hedge funds are holding EQRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for EQRx, Inc. (NASDAQ:EQRXGet Rating).

Institutional Ownership by Quarter for EQRx (NASDAQ:EQRX)

Receive News & Ratings for EQRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EQRx and related companies with MarketBeat.com's FREE daily email newsletter.